Nurix Therapeutics, Inc. (NRIX) balance sheet
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3074% below fair value
$12.85−0.75 (-5.51%)
Close on Nov 20, 2026Market cap $1.40BP/E 5.6Yield 0.00%
Nurix Therapeutics, Inc. balance sheet
Ratios
Latest available, balances at Aug 31, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 41.3%
- Net margin
- 42.0%
- Return on equity, FY2025
- -49.6%
Financial strength
- Current ratio
- 8.44
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 550.9%
Valuation
- P/E ratio
- 5.6
- Price to sales
- 2.00
- Price to book
- 1.45
- Dividend yield
- 0.00%
See a number that looks wrong?